JP2016527257A - ボツリヌス毒素の高純度神経毒成分の製造方法とその使用 - Google Patents
ボツリヌス毒素の高純度神経毒成分の製造方法とその使用 Download PDFInfo
- Publication number
- JP2016527257A JP2016527257A JP2016530382A JP2016530382A JP2016527257A JP 2016527257 A JP2016527257 A JP 2016527257A JP 2016530382 A JP2016530382 A JP 2016530382A JP 2016530382 A JP2016530382 A JP 2016530382A JP 2016527257 A JP2016527257 A JP 2016527257A
- Authority
- JP
- Japan
- Prior art keywords
- botulinum toxin
- clostridium botulinum
- component
- purity
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108030001720 Bontoxilysin Proteins 0.000 title claims abstract description 86
- 229940053031 botulinum toxin Drugs 0.000 title claims abstract description 75
- 231100000189 neurotoxic Toxicity 0.000 title claims abstract description 48
- 230000002887 neurotoxic effect Effects 0.000 title claims abstract description 48
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 47
- 101710138657 Neurotoxin Proteins 0.000 claims abstract description 54
- 239000002581 neurotoxin Substances 0.000 claims abstract description 54
- 231100000618 neurotoxin Toxicity 0.000 claims abstract description 54
- 241000193155 Clostridium botulinum Species 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 42
- 238000012258 culturing Methods 0.000 claims abstract description 11
- 238000012546 transfer Methods 0.000 claims description 28
- 238000000855 fermentation Methods 0.000 claims description 27
- 230000004151 fermentation Effects 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 15
- 238000005259 measurement Methods 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 210000003205 muscle Anatomy 0.000 claims description 10
- 230000001713 cholinergic effect Effects 0.000 claims description 9
- 239000002158 endotoxin Substances 0.000 claims description 8
- 230000030214 innervation Effects 0.000 claims description 7
- 210000003499 exocrine gland Anatomy 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000012925 reference material Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 16
- 239000002245 particle Substances 0.000 description 15
- 231100000765 toxin Toxicity 0.000 description 13
- 239000002609 medium Substances 0.000 description 12
- 239000003053 toxin Substances 0.000 description 12
- 108700012359 toxins Proteins 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 230000000813 microbial effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 231100000331 toxic Toxicity 0.000 description 8
- 230000002588 toxic effect Effects 0.000 description 8
- 101710154606 Hemagglutinin Proteins 0.000 description 7
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 7
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 7
- 101710176177 Protein A56 Proteins 0.000 description 7
- 239000012535 impurity Substances 0.000 description 7
- 239000003381 stabilizer Substances 0.000 description 7
- 102100026038 Lens fiber membrane intrinsic protein Human genes 0.000 description 6
- 101710115990 Lens fiber membrane intrinsic protein Proteins 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 241001112695 Clostridiales Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 208000010118 dystonia Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000000185 hemagglutinin Substances 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 208000014094 Dystonic disease Diseases 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000193403 Clostridium Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000002033 Myoclonus Diseases 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000002577 cryoprotective agent Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000034217 membrane fusion Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- 206010028311 Muscle hypertrophy Diseases 0.000 description 2
- 206010030136 Oesophageal achalasia Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102000007327 Protamines Human genes 0.000 description 2
- 108010007568 Protamines Proteins 0.000 description 2
- 206010040954 Skin wrinkling Diseases 0.000 description 2
- 208000004350 Strabismus Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000013411 master cell bank Methods 0.000 description 2
- 230000012042 muscle hypertrophy Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000006174 pH buffer Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- -1 preparation Substances 0.000 description 2
- 229950008679 protamine sulfate Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 208000018198 spasticity Diseases 0.000 description 2
- 210000005070 sphincter Anatomy 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 206010059237 Auriculotemporal syndrome Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010069632 Bladder dysfunction Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000270722 Crocodylidae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 206010013642 Drooling Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 208000000289 Esophageal Achalasia Diseases 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 206010068737 Facial asymmetry Diseases 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010061991 Grimacing Diseases 0.000 description 1
- 208000004041 Gustatory Sweating Diseases 0.000 description 1
- 208000004095 Hemifacial Spasm Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 208000003028 Stuttering Diseases 0.000 description 1
- 206010048327 Supranuclear palsy Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010044074 Torticollis Diseases 0.000 description 1
- 241000469816 Varus Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 201000000621 achalasia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003131 biological toxin Substances 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 1
- 229940094657 botulinum toxin type a Drugs 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 201000002866 cervical dystonia Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940098753 dysport Drugs 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 238000002567 electromyography Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 108010024001 incobotulinumtoxinA Proteins 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000001352 masseter muscle Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 108010009004 proteose-peptone Proteins 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 229940046307 sodium thioglycolate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000013190 sterility testing Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007888 toxin activity Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000001260 vocal cord Anatomy 0.000 description 1
- 230000037418 vocal dysfunction Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229940018272 xeomin Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M37/00—Means for sterilizing, maintaining sterile conditions or avoiding chemical or biological contamination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/40—Means for regulation, monitoring, measurement or control, e.g. flow regulation of pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Sustainable Development (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
本発明は、ボツリヌス毒素の産生を可能にする条件下で、ボツリヌス菌(Clostridium botulinum)を培養し、ボツリヌス毒素から神経毒成分を分離することにより、ボツリヌス毒素の高純度神経毒成分(highly pure neurotoxic component)を調製するための方法に関する。さらに本発明は、本発明の方法により得られるボツリヌス毒素の高純度神経毒成分、及びその使用に関する。
ボツリヌス毒素は、人にとって最も強力なタンパク質毒素である。これは、神経筋接合部におけるアセチルコリン放出をブロックして、筋肉の脱神経を引き起こすことにより作用する。ボツリヌス毒素はまた、他の末梢のコリン作動性神経末端において活性を有し、その結果、例えば、唾液分泌や発汗の低下、及び顔のラインとしわの低減を引き起こす。これらの作用様式の特異性により、ボツリヌス毒素の臨床応用の範囲が継続的に増大しており、ボツリヌス毒素は、今日、薬理化粧品として広く使用されている。
従って、本発明の目的は、ボツリヌス毒素の高純度神経毒成分を安全な方法で調製するための改善された方法を提供することである。
(a)ボツリヌス毒素の産生を可能にする条件下でボツリヌス菌(Clostridium botulinum)を培養する工程と、
(b)ボツリヌス毒素から神経毒成分を分離する工程と、を含み、
ここで、培養工程(a)と分離工程(b)とは圧力勾配装置中で行われ、この装置は、ボツリヌス菌を培養するための発酵槽を含む第1のアイソレーターユニットと、任意に、第2の又はさらなるアイソレーターユニットと、並びにBSC(生物学的安全キャビネット(Biological Safety Cabinet))の内外への材料の無菌的移送を可能にする移送システムを備えたクラスII BSCである安全作業台とを含む、方法を提供する。
驚くべきことに、これまで考慮されていないが、ボツリヌス毒素の神経毒成分の品質、特に純度に重大な影響を与え得る重要な製造パラメータが存在することが見出された。さらに、本発明の製造方法は、安全、健康、及び環境に関連する法律上の要件を満たし、かつ、安全で無害な作業環境を促進する。すなわち本発明は、製造プロセスの動作のさらなるモードが存在し、これは、環境と人間の健康問題に対して安全なだけでなく、優れた品質、特に優れた品質のボツリヌス毒素の神経毒成分を提供する、という予想外の発見に基づく。
(a)ボツリヌス毒素の産生を可能にする条件下でボツリヌス菌を培養する工程と、
(b)ボツリヌス毒素から神経毒成分を分離する工程と、を含む方法に関する。
安全作業台の構築
DPTE(登録商標)移送システム(Getinge Group)の「アルファ」部分を、HEPAフィルター(Thermo Fisher Scientific, Inc.)を装備したHERAsafe(登録商標)(NSF)クラスII タイプA2生物学的安全キャビネットの右側の壁に取り付けた。剛性の移送容器(ステンレス製DPTE190ベータ容器)は、可動性DPTE(登録商標)「ベータ」部分として使用された。DPTE(登録商標)移送システムの2つの別々のユニット(アルファ部分とベータの部分)は、それぞれ、ドア、ロック、とシール機能が備わっており、アルファ部分とベータの部分内に含まれる無菌又は毒性環境の整合性を破壊することなく、毒性又は病原性物質の連続移送を可能にする。
本発明のアイソレーターユニット内の微生物純度
本研究の目的は、本発明の方法を使用するボツリヌス菌の培養が、無菌条件下で行われることを示すことであった。従って、すべての培養操作は、微生物無しで3回連続の実験でシミュレートされた。すべての培養培地及び添加剤は、無菌試験のための培地(好気性又は嫌気性プロセス条件用のTSB−及びチオグリコール酸培地)に置き換えられた。
アイソレーターユニット内の粒子含有量
微生物汚染や浮遊雑菌の数に加えて、生産品の品質を決定するもう一つの重要な要因は、粒子状不純物の濃度である。これは、(浮遊)粒子からのある生産品の保護が非常に重要である製薬業界で特に重要である。従って、本発明の範囲内で使用されるアイソレーターユニットの異なる作業領域における浮遊粒子(MP18、MP19、及びMP20と指定)の数を測定した。粒子測定は、CAS Clean-Air-Service AG, Switzerlandから販売されている粒子カウンターを用いて行った。結果は以下の表3に示される。
生化学的純度の点での生産品の品質
本発明のアイソレーターを使用し及び使用せずにHall株(ATCC3502)により産生されたボツリヌス菌毒素A型から精製された神経毒成分の異なるロットの総純度と1本鎖含量とを測定した。
微生物純度の点での生産品の品質
生産品の微生物純度(生物負荷)は、本発明に従って調製されたロットの異なるプロセス工程で、Pharm. Eur. 2.6.12 及び USP <61>に従って好気性微生物の生物負荷を、本発明で使用されるアイソレーター技術無しで調製されたロットと比較して、測定することにより評価した。結果は、表6、7、及び8に示される。
エンドトキシン汚染に関連した生産品の品質
本発明に従って調製されたロットのエンドトキシンレベルを、Pharm. Eur. 2.6.14 及び USP <85>に従って測定し、本発明のアイソレーター技術を使用せずに調製されたロットについて測定されたレベルと比較した。測定されたエンドトキシン値は、最終生産品の1mlあたりIUで示される(高純度神経毒成分の100〜500μg/mlを含有する溶液)。結果は表9に示される。
Claims (15)
- ボツリヌス毒素の高純度神経毒成分を調製するための方法であって、
(a)ボツリヌス毒素の産生を可能にする条件下でボツリヌス菌(Clostridium botulinum)を培養する工程と、
(b)ボツリヌス毒素から神経毒成分を分離する工程と、を含み、
ここで、培養工程(a)と分離工程(b)とは圧力勾配装置中で行われ、この装置は、ボツリヌス菌を培養するための発酵槽を含む第1のアイソレーターユニットと、任意に、第2の又はさらなるアイソレーターユニットとを含み、第1のアイソレーターユニットと第2の又はさらなるアイソレーターユニットは、エアロックを介して環境に接続された製造室中に位置し、第1のアイソレーターユニットと第2の又はさらなるアイソレーターユニット中の圧力は、製造室中の圧力より低く、製造室中の圧力は周囲圧力より低く、及び、エアロック中の圧力は周囲圧力より高く、そして、圧力勾配装置は、BSC(生物学的安全キャビネット)の内外への材料の無菌的移送を可能にする移送システムを備えたクラスII BSCである安全作業台をさらに含み、安全作業台もまた製造室中に存在する、上記方法。 - 培養温度は、33.5℃±1.0℃に維持される、請求項1に記載の方法。
- 工程(a)の培養中の細胞密度は、1次濁度基準物質としてホルマジンを使用する濁度測定により追跡される、請求項1又は2に記載の方法。
- ボツリヌス菌の培養は、培養24時間後に到達される1.3±0.3FTUの細胞密度から0.8FTU未満に低下するまで継続される、請求項1〜3のいずれか1項に記載の方法。
- 工程(a)で使用されるボツリヌス菌培養物は、(i)530〜850FTUの細胞密度を有するボツリヌス菌の初期培養物を提供し、(ii)所定量の初期培養物を発酵培地に添加することにより、得られる、請求項1〜4のいずれか1項に記載の方法。
- 初期培養物は、5.0%〜10.0%v/vの量で発酵培地に添加される、請求項5に記載の方法。
- クラスII BSCの移送システムは、互いに着脱可能に接続された、第1の移送ユニットと第2の移送ユニットとを備え、ここで、第1の移送ユニットはBSCの表面に実装されているか、又はBSCの壁に固定されている密閉可能な部分であり、第2の移送ユニットは密閉可能な容器である、請求項1〜6のいずれか1項に記載の方法。
- ボツリヌス菌は、Hall株(ATCC502)を含むボツリヌス菌A型である、請求項1〜7のいずれか1項に記載の方法。
- 1本鎖含量が2.00重量%未満であるボツリヌス菌毒素の高純度神経毒成分。
- 総純度が少なくとも99.90重量%である、請求項9に記載の高純度神経毒成分。
- エンドトキシン含量が5.0IU/ml以下であり、及び/又は総嫌気性生菌数が1cfu/ml未満である、請求項9又は10に記載の高純度神経毒成分。
- 請求項1〜8のいずれか1項に記載の方法により得られる、請求項9〜11のいずれか1項に記載の高純度神経毒成分。
- 請求項9〜12のいずれか1項に記載のボツリヌス菌毒素の高純度神経毒成分と、1種以上の医薬的に許容し得る担体とを含む医薬組成物。
- 医薬として使用される、請求項9〜12のいずれか1項に記載のボツリヌス菌毒素の高純度神経毒成分。
- 筋肉又は外分泌腺の活動亢進性コリン作動性神経支配に関連する疾患又は状態の治療に使用される、請求項9〜12のいずれか1項に記載のボツリヌス菌毒素の高純度神経毒成分。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13003792.2 | 2013-07-30 | ||
EP13003792 | 2013-07-30 | ||
PCT/EP2014/002089 WO2015014487A1 (en) | 2013-07-30 | 2014-07-30 | Process for preparing a highly pure neurotoxic component of a botulinum toxin and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016527257A true JP2016527257A (ja) | 2016-09-08 |
JP6517800B2 JP6517800B2 (ja) | 2019-05-22 |
Family
ID=48906087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016530382A Active JP6517800B2 (ja) | 2013-07-30 | 2014-07-30 | ボツリヌス毒素の高純度神経毒成分の製造方法とその使用 |
Country Status (13)
Country | Link |
---|---|
US (2) | US9937245B2 (ja) |
EP (1) | EP3027641A1 (ja) |
JP (1) | JP6517800B2 (ja) |
KR (1) | KR102272580B1 (ja) |
CN (1) | CN105658662B (ja) |
AU (1) | AU2014298922B2 (ja) |
BR (1) | BR112016001730B1 (ja) |
CA (1) | CA2918233C (ja) |
HK (1) | HK1225744A1 (ja) |
IL (1) | IL243573B (ja) |
MX (1) | MX2016001220A (ja) |
RU (1) | RU2663136C2 (ja) |
WO (1) | WO2015014487A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
US10792344B2 (en) * | 2006-06-29 | 2020-10-06 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of botulinum toxin therapy |
WO2015014487A1 (en) * | 2013-07-30 | 2015-02-05 | Merz Pharma Gmbh & Co. Kgaa | Process for preparing a highly pure neurotoxic component of a botulinum toxin and uses thereof |
EP3590500A1 (en) * | 2014-12-23 | 2020-01-08 | Merz Pharma GmbH & Co. KGaA | Botulinum toxin prefilled container |
WO2016151595A1 (en) | 2015-03-26 | 2016-09-29 | Vensica Medical Ltd. | Ultrasonic urinary bladder drug delivery |
US11529506B2 (en) | 2018-04-01 | 2022-12-20 | Vensica Medical Ltd. | System and method for ultrasonic bladder therapeutic agent delivery |
JP6875318B2 (ja) * | 2018-04-24 | 2021-05-19 | 株式会社日立産機システム | 安全キャビネット |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003505343A (ja) * | 1999-06-07 | 2003-02-12 | メルツ・ウント・コンパニー・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー | ボツリヌス神経毒を含む治療薬 |
JP2005517627A (ja) * | 2000-07-21 | 2005-06-16 | アラーガン、インコーポレイテッド | ロイシンベースモチーフおよびクロストリジウム神経毒 |
JP2009538596A (ja) * | 2005-06-17 | 2009-11-12 | メルツ・ファルマ・ゲーエムベーハー・ウント・コー・カーゲーアーアー | 生物活性化合物を発酵生産するための装置及び方法 |
JP2011074025A (ja) * | 2009-09-30 | 2011-04-14 | Chemo-Sero-Therapeutic Research Inst | ボツリヌス毒素の精製方法 |
JP2013508388A (ja) * | 2009-10-21 | 2013-03-07 | ルバンス セラピュティックス インク. | 非複合ボツリヌス神経毒素を精製するための方法およびシステム |
WO2013053844A1 (fr) * | 2011-10-14 | 2013-04-18 | Getinge La Calhene | Mecanisme de commande a haut niveau de securite pour un dispositif de transfert etanche entre deux volumes clos |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2206337C1 (ru) * | 2002-10-29 | 2003-06-20 | Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" | Лекарственный препарат для лечения мышечных дистоний и способ его получения |
US7339671B2 (en) * | 2004-01-20 | 2008-03-04 | Hong Peng | Apparatus and method for monitoring biological cell culture |
NZ568216A (en) * | 2005-11-17 | 2012-09-28 | Revance Therapeutics Inc | Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins |
AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
JP5746624B2 (ja) * | 2008-08-29 | 2015-07-08 | メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー | 変化した持続性を有するクロストリジウム性神経毒 |
EP2248518B1 (en) * | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
US8129139B2 (en) | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
US20120189677A1 (en) * | 2011-01-20 | 2012-07-26 | Stephen Tonge | Formulations |
WO2015014487A1 (en) * | 2013-07-30 | 2015-02-05 | Merz Pharma Gmbh & Co. Kgaa | Process for preparing a highly pure neurotoxic component of a botulinum toxin and uses thereof |
-
2014
- 2014-07-30 WO PCT/EP2014/002089 patent/WO2015014487A1/en active Application Filing
- 2014-07-30 MX MX2016001220A patent/MX2016001220A/es active IP Right Grant
- 2014-07-30 US US14/908,235 patent/US9937245B2/en active Active
- 2014-07-30 AU AU2014298922A patent/AU2014298922B2/en active Active
- 2014-07-30 EP EP14749719.2A patent/EP3027641A1/en active Pending
- 2014-07-30 JP JP2016530382A patent/JP6517800B2/ja active Active
- 2014-07-30 CN CN201480043265.8A patent/CN105658662B/zh active Active
- 2014-07-30 KR KR1020167004505A patent/KR102272580B1/ko active IP Right Grant
- 2014-07-30 CA CA2918233A patent/CA2918233C/en active Active
- 2014-07-30 BR BR112016001730-7A patent/BR112016001730B1/pt active IP Right Grant
- 2014-07-30 RU RU2016103329A patent/RU2663136C2/ru active
-
2016
- 2016-01-11 IL IL243573A patent/IL243573B/en active IP Right Grant
- 2016-12-07 HK HK16113961A patent/HK1225744A1/zh unknown
-
2018
- 2018-01-26 US US15/881,135 patent/US10653754B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003505343A (ja) * | 1999-06-07 | 2003-02-12 | メルツ・ウント・コンパニー・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー | ボツリヌス神経毒を含む治療薬 |
JP2005517627A (ja) * | 2000-07-21 | 2005-06-16 | アラーガン、インコーポレイテッド | ロイシンベースモチーフおよびクロストリジウム神経毒 |
JP2009538596A (ja) * | 2005-06-17 | 2009-11-12 | メルツ・ファルマ・ゲーエムベーハー・ウント・コー・カーゲーアーアー | 生物活性化合物を発酵生産するための装置及び方法 |
JP2011074025A (ja) * | 2009-09-30 | 2011-04-14 | Chemo-Sero-Therapeutic Research Inst | ボツリヌス毒素の精製方法 |
JP2013508388A (ja) * | 2009-10-21 | 2013-03-07 | ルバンス セラピュティックス インク. | 非複合ボツリヌス神経毒素を精製するための方法およびシステム |
WO2013053844A1 (fr) * | 2011-10-14 | 2013-04-18 | Getinge La Calhene | Mecanisme de commande a haut niveau de securite pour un dispositif de transfert etanche entre deux volumes clos |
Non-Patent Citations (1)
Title |
---|
SIEGEL L. S. ET AL.: "Toxin production by Clostridium botulinum type A under various fermentation conditions", APPL. ENVIRON. MICROBIOL., vol. Vol. 38, JPN6018009441, 1979, pages pp. 606-611 * |
Also Published As
Publication number | Publication date |
---|---|
KR20160036581A (ko) | 2016-04-04 |
CN105658662B (zh) | 2022-05-27 |
US20180147266A1 (en) | 2018-05-31 |
KR102272580B1 (ko) | 2021-07-05 |
AU2014298922B2 (en) | 2018-03-15 |
WO2015014487A1 (en) | 2015-02-05 |
HK1225744A1 (zh) | 2017-09-15 |
JP6517800B2 (ja) | 2019-05-22 |
IL243573B (en) | 2019-03-31 |
RU2663136C2 (ru) | 2018-08-01 |
MX2016001220A (es) | 2016-05-24 |
BR112016001730B1 (pt) | 2023-04-11 |
US10653754B2 (en) | 2020-05-19 |
IL243573A0 (en) | 2016-03-31 |
BR112016001730A2 (pt) | 2017-08-29 |
US20160175407A1 (en) | 2016-06-23 |
CA2918233A1 (en) | 2015-02-05 |
US9937245B2 (en) | 2018-04-10 |
CA2918233C (en) | 2022-08-30 |
RU2016103329A (ru) | 2017-08-31 |
CN105658662A (zh) | 2016-06-08 |
EP3027641A1 (en) | 2016-06-08 |
AU2014298922A1 (en) | 2016-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6517800B2 (ja) | ボツリヌス毒素の高純度神経毒成分の製造方法とその使用 | |
Qin et al. | Formation and properties of in vitro biofilms of ica-negative Staphylococcus epidermidis clinical isolates | |
Bertini et al. | Comparison of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis adhesive properties and pathogenicity | |
JP7460531B2 (ja) | 微生物感染を防ぐための方法および組成物 | |
Novotny et al. | Biofilm biology and vaccine strategies for otitis media due to nontypeable Haemophilus influenzae | |
US12005099B2 (en) | Targeted antimicrobials and related compositions, methods and systems | |
US9662372B2 (en) | Compositions and methods to inactivate and/or reduce production of microbial toxins | |
Ruocco et al. | Bacterial and viral skin diseases | |
US9782492B2 (en) | Stabilization of therapeutic agents to facilitate administration | |
Ali | The Influence of Streptococcus pneumoniae Serine Proteases on Pneumococcal Pathogenesis | |
Vijayakumar et al. | Molecular diagnosis of Pseudomonas aeruginosa contamination in opthalmic viscosurgical devices | |
Naga et al. | Genotypic detection of some Pseudomonas aeruginosa virulence genes among different clinical isolates | |
Kante et al. | In vitro reconstitution of the M. tb proteasome core particle reveals conserved aspects of bacterial proteasome assembly | |
Saleh et al. | INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACEUTICAL SCIENCES | |
DeVore et al. | Skin microbial exposure contributes to allergic disease | |
Jasińska et al. | Evaluation of the role of staphylococci in the pathomechanism of conjunctivitis | |
UA119098C2 (uk) | Спосіб подолання антибіотикорезистентності збудників гнійно-запальних та перипротезних інфекцій суглобів людини | |
Akinjogunla et al. | Heamolytic activities, deoxyribonuclease production and in-vitro flouroquinolones susceptibility profile of aerobic gram positive cocci associated with acne vulgaris | |
Hutchison et al. | Produces a Hemolysin Burkholderia cepacia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170512 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180314 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180320 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180619 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180704 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181211 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190301 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190319 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190418 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6517800 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S201 | Request for registration of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314201 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S221 | Written request for registration of change of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314221 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |